CN115916346A - 用于治疗异常细胞生长的方法 - Google Patents

用于治疗异常细胞生长的方法 Download PDF

Info

Publication number
CN115916346A
CN115916346A CN202180028579.0A CN202180028579A CN115916346A CN 115916346 A CN115916346 A CN 115916346A CN 202180028579 A CN202180028579 A CN 202180028579A CN 115916346 A CN115916346 A CN 115916346A
Authority
CN
China
Prior art keywords
subject
cancer
administered
kras
mek inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028579.0A
Other languages
English (en)
Chinese (zh)
Inventor
J.A.帕赫特
D.帕特森
B.M.斯图格利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of CN115916346A publication Critical patent/CN115916346A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180028579.0A 2020-04-27 2021-04-27 用于治疗异常细胞生长的方法 Pending CN115916346A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015883P 2020-04-27 2020-04-27
US63/015,883 2020-04-27
PCT/US2021/029435 WO2021222278A1 (en) 2020-04-27 2021-04-27 Methods of treating abnormal cell growth

Publications (1)

Publication Number Publication Date
CN115916346A true CN115916346A (zh) 2023-04-04

Family

ID=78332185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028579.0A Pending CN115916346A (zh) 2020-04-27 2021-04-27 用于治疗异常细胞生长的方法

Country Status (11)

Country Link
US (1) US20230201198A1 (https=)
EP (1) EP4142882A4 (https=)
JP (1) JP2023523323A (https=)
KR (1) KR20230011277A (https=)
CN (1) CN115916346A (https=)
AU (1) AU2021263742A1 (https=)
BR (1) BR112022021657A2 (https=)
CA (1) CA3175481A1 (https=)
IL (1) IL297650A (https=)
MX (1) MX2022013430A (https=)
WO (1) WO2021222278A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025261499A1 (zh) * 2024-06-20 2025-12-26 上海科州药物股份有限公司 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
TW202329967A (zh) * 2022-01-21 2023-08-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
EP4469086A4 (en) * 2022-01-25 2026-01-21 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
EP4488272A4 (en) * 2022-02-28 2026-02-25 Wigen Biomedicine Tech Shanghai Co Ltd COMPOUND USED AS A FAK INHIBITOR AND ITS USE
CN118973580A (zh) * 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
JP2025518795A (ja) * 2022-06-03 2025-06-19 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01403A (https=) * 2009-08-24 2015-06-05 Genentech Inc
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
BR112017023821A2 (pt) * 2015-05-06 2018-07-31 Leidos Biomedical Res Inc moduladores de k-ras
AU2018329925B2 (en) * 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
US11666574B2 (en) * 2019-11-27 2023-06-06 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025261499A1 (zh) * 2024-06-20 2025-12-26 上海科州药物股份有限公司 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物

Also Published As

Publication number Publication date
AU2021263742A1 (en) 2022-09-22
EP4142882A4 (en) 2024-06-05
CA3175481A1 (en) 2021-11-04
EP4142882A1 (en) 2023-03-08
KR20230011277A (ko) 2023-01-20
WO2021222278A1 (en) 2021-11-04
IL297650A (en) 2022-12-01
MX2022013430A (es) 2022-11-14
US20230201198A1 (en) 2023-06-29
BR112022021657A2 (pt) 2022-12-20
JP2023523323A (ja) 2023-06-02

Similar Documents

Publication Publication Date Title
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
CN115916346A (zh) 用于治疗异常细胞生长的方法
US20230103007A1 (en) Combination therapy for treating abnormal cell growth
JP7634351B2 (ja) 治療組成物、組み合わせ、及び使用方法
JP2024540015A (ja) 異常な細胞成長を処置するための併用療法
US20250049792A1 (en) Combination therapy for treating abnormal cell growth
US20240115571A1 (en) Combination therapy for treating abnormal cell growth
JP2022172480A5 (https=)
JP2025518795A (ja) 異常な細胞成長を処置するための併用療法
JP2024542019A (ja) 異常な細胞成長を処置する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination